Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. 2010

Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
Department of Geriatric Medicine and Nephrology, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan.

In this prospective, randomized, open-label, blinded end point study, we aimed to establish whether strict blood pressure control (<140 mm Hg) is superior to moderate blood pressure control (> or =140 mm Hg to <150 mm Hg) in reducing cardiovascular mortality and morbidity in elderly patients with isolated systolic hypertension. We divided 3260 patients aged 70 to 84 years with isolated systolic hypertension (sitting blood pressure 160 to 199 mm Hg) into 2 groups, according to strict or moderate blood pressure treatment. A composite of cardiovascular events was evaluated for > or =2 years. The strict control (1545 patients) and moderate control (1534 patients) groups were well matched (mean age: 76.1 years; mean blood pressure: 169.5/81.5 mm Hg). Median follow-up was 3.07 years. At 3 years, blood pressure reached 136.6/74.8 mm Hg and 142.0/76.5 mm Hg, respectively. The blood pressure difference between the 2 groups was 5.4/1.7 mm Hg. The overall rate of the primary composite end point was 10.6 per 1000 patient-years in the strict control group and 12.0 per 1000 patient-years in the moderate control group (hazard ratio: 0.89; [95% CI: 0.60 to 1.34]; P=0.38). In summary, blood pressure targets of <140 mm Hg are safely achievable in relatively healthy patients > or = 70 years of age with isolated systolic hypertension, although our trial was underpowered to definitively determine whether strict control was superior to less stringent blood pressure targets.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008487 Medical History Taking Acquiring information from a patient on past medical conditions and treatments. Medical History, Previous,Past Medical History, Family,Previous Medical History,Family Health History,Family History, Health,Family History, Medical,Family Medical History,History Taking, Medical,Family Health Histories,Family Medical Histories,Health Family Histories,Health Family History,Health History, Family,History, Previous Medical,Medical Family Histories,Medical Family History,Medical Histories, Previous,Medical History, Family,Previous Medical Histories
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002318 Cardiovascular Diseases Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. Adverse Cardiac Event,Cardiac Events,Major Adverse Cardiac Events,Adverse Cardiac Events,Cardiac Event,Cardiac Event, Adverse,Cardiac Events, Adverse,Cardiovascular Disease,Disease, Cardiovascular,Event, Cardiac
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup

Related Publications

Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
December 2009, Nature reviews. Nephrology,
Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
January 2006, European review for medical and pharmacological sciences,
Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
January 2013, Bratislavske lekarske listy,
Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
August 2003, JAMA,
Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
July 1992, Journal of hypertension,
Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
August 1992, Ugeskrift for laeger,
Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
January 1991, Journal of cardiovascular pharmacology,
Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
November 2012, Expert review of cardiovascular therapy,
Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
July 2019, The American journal of medicine,
Toshio Ogihara, and Takao Saruta, and Hiromi Rakugi, and Hiroaki Matsuoka, and Kazuaki Shimamoto, and Kazuyuki Shimada, and Yutaka Imai, and Kenjiro Kikuchi, and Sadayoshi Ito, and Tanenao Eto, and Genjiro Kimura, and Tsutomu Imaizumi, and Shuichi Takishita, and Hirotsugu Ueshima, and
October 2020, Expert opinion on pharmacotherapy,
Copied contents to your clipboard!